Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Albaconozole · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Albaconazole 400 mg cohort 1 | EXPERIMENTAL | Albaconazole 400 mg |
| Placebo cohort 1 | PLACEBO_COMPARATOR | Placebo once daily |
| Albaconozole 400 mg cohort 2 | EXPERIMENTAL | Albaconozole 400 mg every 12 hours |
| Placebo cohort 2 | PLACEBO_COMPARATOR | Placebo every 12 hours |
| Albaconozole 400 mg cohort 3 | EXPERIMENTAL | Albaconozole 400 mg every 8 hours |
| Placebo cohort 3 | PLACEBO_COMPARATOR | Placebo every 8 hours |
| Name | Type | Description |
|---|---|---|
| Albaconozole | DRUG | Albaconozole 400 mg oral once daily for 5 days |
| Placebo | DRUG | Placebo oral once daily for 5 days |
Inclusion Criteria: * Male or female subjects age 18 to 45 * A body mass index (BMI) between 18.5 and 30 kg/m2. * Good physical and mental health. * Vital signs .within the acceptable range. * Electrocardiogram (12-lead) after at least 5 minutes in supine position considered as normal or with findi...
Albaconozole is an investigational small molecule being developed for the treatment of onychomycosis, a fungal infection of the nail. It is currently in Phase 1 clinical development and has not been approved by the FDA.
Albaconozole is being developed by GSK plc, which trades on the New York Stock Exchange under the ticker symbol GSK. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with onychomycosis.
Albaconozole is in Phase 1 clinical development. It is an investigational drug and has not yet received regulatory approval. The drug is being studied for the treatment of onychomycosis, a fungal nail infection.
Albaconozole has one completed Phase 1 clinical trial, identified as NCT01014962. This study, titled "A Study of the Effects of Increasing Doses of a Drug for the Treatment of Nail Fungus," enrolled 24 participants in the United States and was a randomized, double-blind, placebo-controlled trial.
Albaconozole is the primary name for this investigational drug. No alternative names have been reported in the available clinical trial information. It is being studied under the name Albaconozole in the treatment of onychomycosis.